Philippe Camus, M.D.

Dijon, France

Back to drug

The Drug-Induced Respiratory Disease Website

XXIV.a

Pneumonitis (ILD)

See: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf

Publications

Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M

Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.

European journal of dermatology : EJD 2018 02 01;28;129-130 — 2018 02 01 — 129-130

Ali AK, Watson DE

Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.

Pharmacotherapy 2017 Nov;37;1383-1390 — 2017 Nov — 1383-1390

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cs?szi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR,

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine 2016 11 10;375;1823-1833 — 2016 11 10 — 1823-1833

Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.

Drug target insights 2016;10;9-12 — 2016 — 9-12

Martin-Liberal J, Kordbacheh T, Larkin J

Safety of pembrolizumab for the treatment of melanoma.

Expert opinion on drug safety 2015 Jun;14;957-64 — 2015 Jun — 957-64

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Lancet (London, England) 2014 Sep 20;384;1109-17 — 2014 Sep 20 — 1109-17

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

The New England journal of medicine 2013 Jul 11;369;134-44 — 2013 Jul 11 — 134-44